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overlaps in scope and arbitrary decisions on 
wording and substructuring inhibit their use 
in combination. These issues present difficul-
ties for checklist users, especially those who 
routinely combine information from several 
disciplines. Here we explore some of the issues 
arising from the development of checklists in 
relative isolation, discuss the potential ben-
efits of greater coordination and describe the 
mechanisms we have put in place to facilitate 
such coordination. In summary, we present 
the MIBBI project (http://www.mibbi.org/), 
which maintains a web-based, freely accessi-
ble resource for checklist projects, providing 
straightforward access to extant checklists (and 
to complementary data formats, controlled 
vocabularies, tools and databases), thereby 
enhancing both transparency and accessibil-
ity, as discussed above. MIBBI is managed by 
representatives of its various participant com-
munities and is fully open to comment from 
any interested party. Our goal is to facilitate 
the development of an integrated checklist 
resource site for the wider bioscience com-
munity.
guidelines for reporting proteomics experi-
ments and describing systems biology models 
are gaining broader support in their respec-
tive database communities8,9; and progress is 
being made toward the standardization of the 
reporting of clinical trials in the medical litera-
ture10. Such minimum information checklists 
promote transparency in experimental report-
ing, enhance accessibility to data and support 
effective quality assessment, increasing the 
general value of a body of work (and the com-
petitiveness of the originators).
Collaborative minimum information 
checklist development projects for diverse 
biologically and technologically delineated 
subject areas are ongoing. A special issue of 
the journal OMICS11 included invited pieces 
from eight communities supporting mini-
mum information checklist development 
projects. However, until recently there were 
no mechanisms for such projects to coordi-
nate their development. Consequently, the full 
range of checklists can be difficult to estab-
lish without intensive searching, and tracking 
their evolution is nontrivial. Furthermore, 
To fully understand the context, methods, data and conclusions that pertain to an 
experiment, one must have access to a range of 
background information. However, the current 
diversity of experimental designs and analyti-
cal techniques complicates the discovery and 
evaluation of experimental data; furthermore, 
the increasing rate of production of those data 
compounds the problem. Community opinion 
increasingly favors that a regularized set of the 
available metadata (‘data about the data’) per-
taining to an experiment1,2 be associated with 
the results, making explicit both the biological 
and methodological contexts. Many journals 
and funding agencies now require that authors 
reporting microarray-based transcriptom-
ics experiments comply with the Minimum 
Information about a Microarray Experiment 
(MIAME) checklist3 as a prerequisite for pub-
lication4–7. Similarly, minimum information 
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soring practitioner communities, but such 
checklists should also, we believe, be designed 
to anticipate ‘cross-domain’ integrative activi-
ties. It is unhelpful to confine checklists for the 
use of particular technologies to a limited set of 
biologically delineated communities, or to con-
ceive of any such community as being restricted 
to a particular set of technologies. Consider 
mass spectrometry, which is used in the study 
of proteins, metabolites and even to sequence 
genes; or consider toxicology, which may use 
any or all of the available ‘omics’ technologies 
in pursuit of the greater understanding of the 
mode of action of a particular compound. 
Clearly the vistas from any two locations can 
overlap substantially, so who can claim sole 
ownership of any part of the scientific land-
scape? Initiatives such as that to harmonize the 
general increase in frequency of data-driven (as 
opposed to hypothesis-driven) investigations 
in recent years. These trends have together 
made the need for coordination and harmo-
nization between groups developing data for-
mat and reporting standards a critical issue10. 
Throughout this document, the words ‘stan-
dard’ and ‘standardization’ are used to refer 
only to the regularization of data capture, 
representation, annotation or reporting, as 
opposed to best practices for experimental pro-
cedures. Specifically, we refer to three kinds of 
reporting standards: (i) minimum information 
checklists or guidelines; (ii) formats (syntax); 
and (iii) controlled vocabularies and ontolo-
gies (semantics).
It is clear that checklists should be developed 
through close consultation with their spon-
On the need to harmonize minimum 
information checklists
The current proliferation of documents speci-
fying the minimum information to provide 
when reporting particular kinds of experi-
mental data has in large part been driven by 
the advent of a range of so-called ‘omics’ (and 
allied) technologies, many of which operate in 
a high-throughput mode, thereby generating 
large volumes of data. These documents have 
been developed independently for the most 
part, and as a result feature many arbitrary dif-
ferences in both wording and structure. This 
greatly complicates the integration of data sets 
that comply with different minimum informa-
tion checklists. Increasing appreciation of the 
potential value accruing to ‘secondary use’ of 
data is also a significant factor8, reflecting the 
CIMR (http://msi-workgroups.sourceforge.net/)
The Metabolomics Standards Initiative’s Core Information for 
Metabolomics Reporting (CIMR) comprises modules for particular 
aspects of metabolomics workflows; various biological disciplines 
(for example, microbiology, mammalian biology, plant biology); 
analytical techniques such as chromatography and NMR; and the 
use of various statistical techniques.
MIACA (http://miaca.sourceforge.net/)
The Minimum Information About a Cellular Assay (MIACA) 
checklist relates to the perturbation of cells with various classes of 
molecule, such as small interfering RNA (siRNA) or small chemical 
compounds. It also provides guidance on the representation of 
environmental stressors such as temperature shift or starvation, 
and combinations thereof.
MIAME (http://www.mged.org/Workgroups/MIAME/miame.html)
The Microarray and Gene Expression Data Society’s well- 
established Minimum Information About a Microarray Experiment 
(MIAME) checklist relates to the use of (micro)arrays (most 
commonly to assay messenger RNA abundance) and analysis of the 
data generated.
MIAME/Nutr (http://www.mged.org/Workgroups/rsbi/rsbi.html)  
MIAME/Tox (http://www.mged.org/Workgroups/rsbi/rsbi.html)  
MIAME/Env (http://nebc.nox.ac.uk/miame/miame_env.html)  
MIAME/Plant (http://miame-plant.sourceforge.net/)
The MIAME checklist has recently been extended to capture 
parameters appropriate to nutrigenomics (/Nutr), toxicogenomics  
(/Tox), environmental biology (/Env) and phytology (/Plant), in each 
case adding relevant information about the background to the 
experiment.
MIAPA (http://www.mibbi.org/index.php/projects/MIAPA)
The Minimum Information About a Phylogenetic Analysis 
(MIAPA) checklist relates to the use of software to align 
biological sequences, and the subsequent use of algorithms to 
construct phylogenies or cladograms and to draw inferences from 
them.
MIAPE (http://www.psidev.info/miape/)
The Minimum Information About a Proteomics Experiment (MIAPE) 
checklist comprises modules for reporting the use of and the 
interpretation of data from various analytical techniques, such as 
mass spectrometry, gel electrophoresis or liquid chromatography. 
Modules addressing the description of the biological material under 
study are planned.
MIARE (http://www.miare.org/)
The Minimum Information About an RNA interference Experiment 
(MIARE) checklist identifies minimal reporting parameters for 
aspects of high-throughput RNA interference (for example, 
siRNA and small hairpin RNA) screens, usually in conjunction 
with cellular assays (compare MIACA checklist, above) and flow 
cytometry (compare MIFlowCyt checklist, next).
MIFlowCyt (http://flowcyt.sourceforge.net/)
The Minimum Information for a Flow Cytometry Experiment 
(MIFlowCyt) checklist addresses the use of flow cytometry, especially 
to measure the phenotype and function of cells; information is 
required about the sample analyzed; the probe, fluorochrome and 
instrument used; and the analysis of the data collected.
MIGen (http://www.mibbi.org/index.php/projects/MIGen)
The Minimum Information about a Genotyping experiment (MIGen) 
checklist addresses genotyping based on single-nucleotide and 
microsatellite-repeat polymorphisms, and genetic association and 
linkage analysis in humans, with special reference to immunology.
MIGS/MIMS (http://gensc.org/)
The Minimum Information about a Genome Sequence (MIGS) 
checklist is an extension of the metadata traditionally captured by 
the International Nucleotide Sequence Databases (DDBJ, EMBL 
and GenBank). It captures information relating to nucleic acid 
sequence, location and sequencing method. The description of 
habitat is also being extended by means of the tightly integrated 
Minimum Information About a Metagenomic Sequence/Sample 
(MIMS) checklist.
 (continued)
Box 1  Checklist development projects registered with MIBBI
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developers to ensure that their products can 
handle the specified data appropriately; or for 
instrument vendors to offer checklist-compli-
ant data set export from their instrument man-
agement software. It is also likely that journals 
and funders will adopt some checklists whole-
sale, incorporating them into their guidance 
for authors and applicants.
A resource for minimum information 
checklists: MIBBI
The activities of standardization groups often 
go unpublished and may not be accessible at 
all, practically speaking. A common resource 
for minimum information checklists, coordi-
nated by a group of community representatives 
from ongoing standardization activities, will 
help unify the standardization community. It 
will assist in recruiting participants to ongoing 
activities and it will help to maintain transpar-
ency of process by providing access to project-
related information (for example, status, key 
players and plans). It will also ease the establish-
ment of new initiatives by providing answers 
to questions such as, “How do we get started?” 
and, importantly, “How do we make sure we 
don’t reinvent the wheel?”. Such an effort will 
improve communication, knowledge transfer 
and integration between checklist development 
projects hailing from different scientific com-
munities and, further, between different kinds 
of reporting standards projects, ultimately 
resulting in simplified access to a broad range 
of capturing a wide range of (meta)data in a 
consistent manner; Reporting Structure for 
Biological Investigations (RSBI)15 provides a 
foundational lingua franca for standards proj-
ects (described further below) and builds on 
this to define a simple, but general, tabular for-
mat (ISA-TAB)16 aligned with FuGE; Ontology 
for Biomedical Investigations (OBI; http://obi.
sourceforge.net/) is a broad-scope ontology 
providing a self-compatible set of terms with 
which to describe a wide range of biological 
and medical studies; and the Open Biomedical 
Ontologies (OBO) Foundry17 (http://obo-
foundry.org/) coordinates the development 
of a set of ‘gold-standard reference ontologies’ 
(including OBI) that can be used in combina-
tion because they are based on common prin-
ciples and, importantly, because procedures 
have been established to ensure resolution of 
the conflicts that might arise where ontologies 
overlap.
Although the primary purpose of minimum 
information checklists is to guide researchers 
in reporting their experiments, they can, for 
the kinds of projects mentioned above, serve 
a valuable role as key ‘use cases’, in that they 
represent the distilled opinion of a particular 
community on the information that should 
normally be captured to effectively describe a 
particular kind of experiment. They therefore 
provide a realistic scenario with which to test 
any resource’s suitability for use by a commu-
nity; for example, for software and database 
description of ‘sample’ (the biological source 
material for a study)12 or to develop (separa-
ble) community-level extensions to shared core 
standards such as MIAME to better describe 
domain-specific studies (for example, in envi-
ronmental biology13) are clearly the order of 
the day. This throws into relief an important 
division between analytical approaches and 
the various subdivisions of the biosciences. 
Checklists that do not span that division will 
always achieve greater utility because they can 
be reused more straightforwardly to construct 
new, made-to-order checklists for a wider range 
of workflows.
The management of information from 
experiments (both data and metadata) requires 
the adoption of reporting standards that ensure 
transparency and interoperability and that 
facilitate the integration and exchange of data 
from different sources. Reporting standards 
also facilitate the execution of more powerful 
queries against repositories of experimental 
data because core information will be regular-
ized and extended information will be supplied 
in a well characterized manner. This long-term 
vision will require significant effort and buy-in 
from a range of scientific communities spread 
across many nations, but development of 
some of the kinds of component required to 
establish such infrastructure is well underway: 
Functional Genomics Experiment14 (FuGE) is 
an object-oriented data model (with an asso-
ciated XML-based syntactic format) capable 
MIMIx (http://www.psidev.info/)
The Minimum Information required for reporting a Molecular 
Interaction experiment (MIMIx) checklist includes the identity 
of molecules that participate in an interaction (with accession 
number), the methods by which both the interaction and the 
identity of the participants were established and the role of these 
molecules in the context of the experiment (as distinct from their 
biological role).
MIMPP (http://www.interphenome.org/)
The Minimum Information for Mouse Phenotyping Procedures 
relates to the diverse protocols used to characterize the phenotype 
of a mouse. The checklist addresses both behavioral and 
physiological traits.
MINI (http://carmen.org.uk/standards/)
The Minimum Information about a Neuroscience Investigation 
(MINI) checklist identifies the minimum information required to 
report the use of electrophysiology in a neuroscience study.
MIQAS (http://miqas.sourceforge.net/)
The Minimum Information for QTLs and Association Studies 
(MIQAS) checklist relates to the mapping of quantitative trait loci 
(QTLs) and their association with genetic markers.
MIqPCR (http://www.rdml.org/)
The Minimum Information about a Quantitative Polymerase Chain 
Reaction experiment checklist addresses the minimal reporting 
parameters for experiments involving quantitative PCR.
MIRIAM (http://biomodels.net/miriam)
The Minimum Information Requested In the Annotation of 
biochemical Models (MIRIAM) checklist offers formal requirements 
for describing theoretical models of biochemical systems.
MISFISHIE (http://mged.sourceforge.net/misfishie/)
The Minimum Information Specification For In Situ Hybridization 
and Immunohistochemistry Experiments (MISFISHIE) checklist21 
addresses visual interpretation–based tissue gene expression 
localization experiments, such as those using in situ hybridization or 
immunohistochemistry.
STRENDA (http://www.strenda.org/)
The Standards for Reporting Enzymology Data (STRENDA) initiative, 
along with participants in the biannual ESCEC (Experimental Standard 
Conditions of Enzyme Characterizations) symposia, maintain a series 
of checklists addressing the description of enzymatic activity data and 
the experiments in which these data were collected. These checklists 
are subject to permanent review by the community involved.
Box 1  Checklist development projects registered with MIBBI (continued)
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Table 1  The composition of each of the 21 checklists visible through the MIBBI Portal
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Study inputs
Study design ● 17
Generic organism ● 18
Cells/microbes 7
Plant 2
Animal 3
Mouse 1
Human 3
Population 3
Environmental sample 2
Environment/habitat 6
In silico model 2
Study procedures
Organism maintenance 1
Animal husbandry 4
Cell/microbe culture 4
Plant cultivation 2
Acclimation 1
Preconditioning/pretreatment ● 7
Organism manipulation 4
Assay inputs
Generic study input 5
Organism part ● 14
Organism state 4
Organism trait 6
Biomolecule 3
Synthetic analyte ● 4
Silencing RNA reagent 2
Sample collection 3
Sample processing 12
Sample storage 2
Sample transport 1
Assay procedures
Detection/tagging/staining 13
Generic analysis 3
Array-based assay ● 10
Capillary electrophoresis ● ● 3
Cell phenotyping ● 2
Clinical test/examination 3
Column chromatography 3
Electrochemical detection ● 1
Electrophysiology mensuration 1
Enzyme activity assay 1
Flow cytometry 2
FTIR spectroscopy ● 1
Gel electrophoresis 2
Image acquisition ● 8
Mass spectrometry 3
Molecular interaction detection 1
(continued)
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with their checklist’s developmental status and, 
where applicable, an indication that a checklist 
is composed of separate modules.
By signing up with the MIBBI Portal and 
thereby attracting more intensive peer over-
sight, communities will come under pressure 
to maintain their checklists in light of scientific 
advances, to provide open access to their pro-
cesses and to respond to comments. We hope 
that one of the primary benefits of the Portal 
will be to raise awareness in the biological and 
medical communities of the importance of 
standardization, thereby increasing willing-
ness among researchers to become involved 
in guiding and shaping the evolution of 
these activities. We hope it will help push the 
of the underlying project. The Portal provides 
summary information for each of the MIBBI-
affiliated projects; specifically, the primary 
contact(s) and website (where available), an 
overview of the project’s scope and develop-
mental status and links to publications and 
other documents (including, where possible, 
a link to the most recent version of that proj-
ect’s checklist). Information available through 
the Portal will be updated as circumstances 
change (for example, if a project is fragmented 
or amalgamated, or simply becomes dormant). 
Box 1 offers brief textual descriptions of the 
21 projects currently registered with MIBBI; 
Table 1 provides a representation of the con-
cepts that comprise each project’s scope, along 
of richly annotated data for the end user. Thus, 
we have established the MIBBI project—a web-
based, communal resource designed to act as 
a ‘one-stop shop’ for those exploring the range 
of extant checklist projects and to foster collab-
orative, integrative development of checklists 
(http://www.mibbi.org/).
MIBBI has two key parts. The first is the 
‘Portal’, which exists simply to raise awareness 
of, and afford more straightforward access to, a 
wide range of checklists by providing research-
ers, journal editors, reviewers, funders and the 
wider community of checklist developers with 
a quick and simple way to discover (whether 
there is) a checklist addressing a particular 
area and to establish the scope and progress 
Table 1  The composition of each of the 21 checklists visible through the MIBBI Portal (continued)
Concept ●
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Mouse phenotyping 1
NMR spectroscopy ● 2
Nucleic acid sequencing 3
Quantitative PCR amplification 1
Toxicology assay 2
Data analysis
Generic data analysis ● 11
Clustering 2
Image characterization ● 7
Population genetic analysis 2
Gene function assignment 11
Genetic association/mapping 2
Relative or absolute quantitation 8
Sequence assembly 1
Data description
Generic data description ● 7
Confidence indicator 4
Data availability
Raw data 12
Processed data 11
Administrative
Citations et cetera 19
Personnel 18
Supporting data 7
Column totals 35 22 14 21 27 19 21 9 21 20 13 24 8 7 11 13 11 6 5 12 12
Table key
Granularity Coarse Medium Fine
Maturity
●  
Planned
●  
Drafting
● 
Released
● 
Published
Concepts (row headings) were derived as described in the Methods section, constructed exclusively for the purpose of identifying overlaps between checklists. Because the 
concepts vary widely in breadth of scope, the number of concepts addressed by any one project is not necessarily indicative of the extent of that project’s actual guidelines. Color 
codings of cells and bullets indicate granularity of coverage and developmental status, respectively. Some bullets have been placed within the matrix itself to provide a finer-grained 
view of developmental status; cells lacking bullets inherit the overall status of their project (that is, the bullet at that column’s head). Row and column totals (counting presence or 
absence only) are provided in the rightmost column and bottom row. Analyses of these data are provided in Figure 1 and in Supplementary Figures 1 and 2.
aThe specification is provided as a suite of related documents
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Bioinformatics Institute and was funded 
by the UK’s Biotechnology and Biological 
Sciences Research Council. This first meeting 
rapidly reached consensus on a work plan and 
established working groups to begin to gener-
ate MIBBI Foundry modules. A full workshop 
report is available through the project’s web-
site (http://www.mibbi.org/).
High-level abstractions of the components 
of experimental workflows offer a useful frame-
work to support the integration of checklists. 
An example of a group attempting to produce 
such abstractions is the RSBI working group14, 
which interacts with a number of other initia-
tives18–20 in working toward an integrated view 
of functional genomics investigations. In their 
characterization, an ‘Investigation’ is a self-con-
tained unit of scientific enquiry, with a holis-
tic hypothesis or objective and a design that 
is defined by the relationships between one or 
more ‘Studies’ and ‘Assays’. A Study represents 
the part of an experiment containing informa-
tion about the biological material, and an Assay 
is the part using particular technologies that 
produce data. The RSBI’s proposed framework 
of well defined, high-level abstractions (such 
as the three just described) was developed 
because the above concepts are duplicated, but 
differently named, across different checklists, 
confounding the uniform description of the 
diverse events that may occur within a Study 
(sensu RSBI).
Foundational analysis of MIBBI-
registered projects
To better understand the scope and depth of 
the various MIBBI-registered minimum infor-
mation checklists, we performed a comparative 
analysis. Table 1 presents a projection of the 
various checklists onto a coarse-grained list of 
ad hoc concepts, constructed exclusively for the 
purpose of identifying overlaps between those 
existing checklists; note that the concepts vary 
widely in breadth of scope (see Box 2), so the 
number of concepts addressed by any one 
project is not necessarily indicative of the size 
of that project’s guidelines, as some concepts 
cover whole workflows (for example, ‘nucleic 
acid sequencing’). It will be clear to the reader 
that some of these concepts, such as ‘organism’, 
are almost universal, whereas others, such as 
‘quantitative PCR amplification’, may relate to 
one group alone. It is also clear that the depth 
of description required in relation to par-
ticular concepts varies widely across projects, 
suggesting a ‘tiered’ approach; that is, some of 
the checklist modules generated by the MIBBI 
Foundry should, in some cases, require a differ-
ent depth of description contingent on the par-
ticular experimental context. Row and column 
totals (summing presence or absence only) are 
the Foundry activity. Furthermore, attempts 
to integrate checklists through the Foundry 
should be managed through a community-
driven mechanism that relies primarily on 
openness and transparency to encourage (vol-
untary) uptake. The MIBBI Foundry is 
modeled on the OBO Foundry17, a newly 
established initiative in the field of ontology 
development. Communities working together 
through MIBBI will produce orthogonal (that 
is, non-overlapping) minimum information 
modules, just as the communities involved 
with the OBO Foundry are aiming to produce 
orthogonal ontologies.
Foundry activities must be driven by 
the member communities (acting through 
their representatives). In preparation for the 
Foundry activity, we have established dis-
cussion forums to facilitate communication 
between communities to encourage discussion 
of the overlaps between checklists. Exploratory 
studies are ongoing, based on coarse com-
parison tables (such as Table 1) that high-
light areas addressed by one or more projects. 
The next stage is to use ‘groupware’ (that is, 
a wiki or an online document-sharing tool) 
to jointly develop modules for those shared 
areas. Throughout this gradually intensifying 
activity, we will hold regular face-to-face meet-
ings that act as development workshops and 
promote good working relationships between 
project representatives. The first such meet-
ing was held in April 2008 at the European 
community to strive for compliance in their 
own publication and data-dissemination prac-
tices by facilitating access to relevant informa-
tion about these efforts. We also see this as an 
excellent artifact with which to promote col-
laboration within and between communities: 
the principle we endorse is that if a broadly 
relevant effort already exists (for example, 
describing the use of a particular technol-
ogy), individuals with an interest should seek 
to join that effort rather than compete with it. 
However, it is crucial that MIBBI never pre-
clude revisions or innovations; the hoped-for 
kudos and enhanced coordination accruing to 
membership should not translate to a possible 
dominion.
The second key part of MIBBI is the 
‘Foundry’. Communities can, if motivated, sign 
up with the Foundry to jointly examine ways 
to refactor the checklists over which they have 
control and then to develop a suite of self-con-
sistent, clearly bounded, orthogonal, integrable 
checklist modules. These modules will then be 
made available to the community through the 
MICheckout tool, a collaborative development 
between the European Bioinformatics Institute 
and the UK Natural Environmental Research 
Council’s Environmental Bioinformatics 
Centre. MICheckout will assist users in com-
piling the correct list of modules and down-
loading them in a form that they can use. Note 
that registering a project with MIBBI implies 
no commitment by a project to participate in 
Box 2  MIBBI methods
For the foundational analysis, we created a base data set (Table 1) by analyzing the content 
of the registrant projects’ checklists and deriving the list of 65 concepts presented. These 
concepts were created for the purpose of this analysis and are not taken from any other 
source, although the meanings of ‘study’ and ‘assay’, where they appear, are as set by 
the RSBI. The concepts have been designed to capture the content of a checklist in an 
intuitive but compact manner, which means that some concepts represent a large body 
of methods and technologies (for example, ‘nucleic acid sequencing’). However, where 
a component of such a broad concept was found to have an analog in another project’s 
checklist, that component was factored out to form a new standalone concept (for example, 
‘detection/tagging/staining’ is a concept common to workflows involving microarraying, gel 
electrophoresis and mass spectrometry), the better to highlight the commonalities between 
projects. Note also that some concepts are just ‘naturally’ narrow (such as ‘citations et 
cetera’, which addresses external referencing, for example, to published papers or to data 
sets in repositories). The 65 ad hoc concepts thus derived have been used throughout 
the analyses presented here. In some cases, concepts in Table 1 are indented; this is 
to indicate that they represent a further specialization of the last less-indented concept 
above (for example, a ‘human’ is an ‘animal’, which is a ‘generic organism’). However, 
the specialization of a more general concept does not imply that those concepts’ content 
overlaps as might be the case in an ontology (that is, ‘human’ cannot be taken to imply 
‘animal plus additional information’), and having a specific requirement (for example, 
‘human’) does not imply that there is also generic (that is, for any organism) guidance. The 
concepts have been represented thus simply to guide the eye while demonstrating that a 
project may address a concept in a generic or a specific manner, or may actually provide 
both kinds of requirement (six projects do this, to varying degrees).
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MIBBI Foundry, building on the foundational 
analysis presented here) our long-term vision 
of a fully integrated, broad-coverage suite of 
minimum information checklists, in step with 
the general movement in the biological and 
medical sciences toward integrated, multifac-
eted investigations of the puzzles that remain 
to be addressed in the postgenomic era.
Note: Supplementary information is available on the 
Nature Biotechnology website.
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MIBBI will increase connectivity between 
minimum information checklist projects and, 
more widely, will increase connectivity with 
projects developing other kinds of informatics 
resources (formats, vocabularies, tools, data-
bases). The resultant evolution of an interdis-
ciplinary community of checklist developers 
will bring into focus the collective expertise 
residing in that group. It will accelerate the 
establishment of mutually beneficial networks 
of expertise, and it will advance (through the 
provided in Table 1; the row totals have been 
used to rank-order concepts by ‘popularity’. 
Figure 1 lists the eighteen most common ad 
hoc concepts.
To support greater understanding of the 
relatedness of the different projects and of 
the various ad hoc concepts, we conducted 
two pairwise comparisons using the data pre-
sented in Table 1: concepts ‘shared’ between 
pairs of projects, and pairs of concepts occur-
ring together within projects (counting pres-
ence or absence only). Supplementary Figure 
1 online illustrates the interrelatedness of the 
21 MIBBI-registered projects both as a tree and 
as an interaction graph. These two representa-
tions make clear that there is a subset of closely 
related (that is, heavily overlapping) projects; 
these are, broadly speaking, the ‘technologi-
cally delineated’ projects, such as MIAME and 
the Minimum Information About Proteomics 
Experiment (MIAPE). It is also clear that there 
are many projects that are ‘related’ (accord-
ing to the tree, if considered in isolation) 
only by their low degree of relatedness to any 
other project (as the interaction graph makes 
explicit). Supplementary Figure 2 online pres-
ents an unrooted tree expressing the relatedness 
of individual concepts. Although this analysis 
is based on the various projects’ scopes, rather 
than any sense of the similarity of the concepts 
themselves, it produces some sensible-looking 
groupings. All the highly ranked (‘high-prior-
ity’) concepts from Figure 1 cluster together 
because most of the projects share an interest 
in many of them, so they are often found to 
occur together in individual projects’ scopes. 
Such an analysis can help in deciding how the 
ad hoc concept-based survey presented in Table 
1 should be used as we draft the checklist mod-
ules that will ultimately be developed by partic-
ipants in the MIBBI Foundry’s activities (that 
is, whether some concepts can be combined, 
whether others should be further subdivided, 
and so on).
These various analyses make two things plain: 
first, that there are standout priority areas for 
the MIBBI Foundry (for example, the uniform 
description of an organism); and second, that 
there are many niche areas where little or no 
collaborative activity is required (for example, 
the process of mouse phenotyping)—a simple 
endorsement by MIBBI of the products of a 
particular project being sufficient, as things 
stand.
Conclusions
By providing easy access to checklist develop-
ment projects and their products, MIBBI will 
facilitate the discovery of checklists appropri-
ate to the needs of practitioners from diverse 
parts of biological and biomedical science (the 
0 5 10 15 20
Citations et cetera
Generic organism
Personnel
Study design
Organism part
Detection/tagging/staining
Raw data
Gene function assignment
Processed data
Array-based assay
Generic data analysis
Image acquisition
Relative or absolute quantification
Cells/microbes
Image characterization
Preconditioning/pretreatment
Supporting data
Sample processing
Figure 1  The eighteen highest-ranked ad hoc concepts, according to Table 1. This highlights priority 
areas for the MIBBI Foundry (though the concepts used here may not directly translate into guidelines 
modules).
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